Speed and efficiency – from discovery to approval to market and beyond – are fundamental to the success of today’s biopharmaceutical enterprise. Making decisions faster and introducing efficiencies at every stage of the drug development cycle is now accepted dogma, but the search continues for something more transformative to boost pipeline productivity and growth.
One answer may lie in the arrival of replicable, synthetic versions of DNA, the design atelier behind the most cost-effective,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?